Scan Results
Daily timeframeFresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The $9.99B market capitalization puts FME.DE squarely in mid-cap range for its industry. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Market Cap
$9.99B
Beta
0.82
P/E (TTM)
11.37
P/E (Fwd)
8.41
EPS (TTM)
$3.27
EPS (Fwd)
$4.42
ROE
7.8%
ROA
3.6%
Cash
$1.24B
Total Debt
$11.04B
Free CF
$1.67B
52W Change
-26.1%
Annual Financials
Cash vs Debt
Fresenius Medical Care AG carries $11.04B in total debt against $1.24B in cash reserves — debt is roughly 8.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $1.67B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 7.8%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.6% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $19.40B (2022) to $19.63B (2025).
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Fresenius Medical Care AG's trajectory.